DRNA earnings

– Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD) – – Company Plans to Unveil First GalXC-Plus™ Extrahepatic Target in Early 2022 – – Cash Runway Extends Into 2025 – – Company to Host Conference Call Today at 8:30 a.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update. "We had a

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4

– Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria – – Announced U.S. Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) Application for DCR-AUD for Alcohol Use Disorder – – Announced Interim Phase 1 Results and Initiated Patient Dosing in ESTRELLA Phase 2 Study of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (AATLD) – – Received $10.0 Million Milestone Payment Following FDA Acceptance of Lilly's Second GalXC RNAi IND Application Under Companies' Global Research Collaboration and Licensing Agreement – – Company

– Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion; Key Secondary Endpoint Also Achieved; Robust Efficacy Seen in PH1 Participants – – Nedosiran Was Generally Well Tolerated in PHYOX2 With a Safety Profile Similar to Previously Reported PHYOX Trial Results – – Results Further Validate GalXC™ RNAi Technology Platform and its Ability to Silence Disease-Driving Genes – – Management to Host Conference Call and Webcast Today at 4:30 p.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutic

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2021 financial results before market open on Monday, Aug. 9, 2021. Management will host a conference call at 8:00 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4